Products Cited in Publications Worldwide A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies

A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies

Liu, Zhiwei; Liu, Yingluo; Qian, Lili; Jiang, Shangwen; Gai, Xiameng; Ye, Shu; Chen, Yuehong; Wang, Xiaomin; Zhai, Linhui; Xu, Jun

DOI: PMID:

Abstract

KRAS mutant cancer, characterized by the activation of a plethora of phosphorylation signaling pathways, remains a major challenge for cancer therapy. Despite recent advancements, a comprehensive profile of the proteome and phosphoproteome is lacking. This study provides a proteomic and phosphoproteomic landscape of 43 KRAS mutant cancer cell lines across different tissue origins. By integrating transcriptomics, proteomics, and phosphoproteomics, we identify three subsets with distinct biological, clinical, and therapeutic characteristics. The integrative analysis of phosphoproteome and drug sensitivity information facilitates the identification of a set of drug combinations with therapeutic potentials. Among them, we demonstrate that the combination of DOT1L and SHP2 inhibitors is an effective treatment specific for subset 2 of KRAS mutant cancers, corresponding to a set of TCGA clinical tumors with the poorest prognosis. Together, this study provides a resource to better understand KRAS mutant cancer heterogeneity and identify new therapeutic possibilities.

Purchased from AmBeed

SHP099 HCl

A1407691801747-11-498+%

SHP099 HCl

12.0/1mg

Detail
Ulixertinib

A162263869886-67-999%

Ulixertinib

41.0/10mg

Detail
EPZ004777

A1626901338466-77-599%

EPZ004777

338.0/50mg

Detail
Pinometostat

A2282481380288-87-898%

Pinometostat

441.0/100mg

Detail
SGC0946

A7025741561178-17-399%

SGC0946

236.0/25mg

Detail